Drugs News and Research

RSS

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.

7 Jan 2011

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

7 Jan 2011

Opinions: Global health top foreign policy issue; Global food security; Opiate-substitution programs in Eastern Europe; Feed the future; Foreign aid lessons

In response to a story examining 2011's top foreign policy issues, Serra Sippel, president of the Center for Health and Gender Equity, writes in a letter to the editor, published in The Hill, that "[g]lobal health was disturbingly absent from" the story. "Global health policy is at a critical turning point right now with the impending implementation of President Obama's Global Health Initiative, which will change our fundamental approach to health programs and policy," according to Sippel.

7 Jan 2011

HRG protein inhibits tumor growth and metastasis: Study

Most cancer tissues are invaded by inflammatory cells that either stimulate or inhibit the growth of the tumor, depending on what immune cells are involved. Now a Swedish-Belgian research team has shown that a protein that naturally occurs in the body, HRG, inhibits tumor growth and metastasis into secondary organs by activating specific immune cells.

7 Jan 2011

Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the first patient has been dosed in Japan in a Nippon Kayaku sponsored Phase 1 study of apaziquone in bladder cancer.

7 Jan 2011

X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs, and X-BODY BioSciences, a developer of monoclonal antibody therapeutics, today announced a multi-target research collaboration.

7 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

Virdante Pharmaceuticals receives US key patent for Sialic Switch technology

Virdante Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has granted a key patent that supports the Company's "Sialic Switch" technology for improving the anti-inflammatory activity of antibody-based drugs to treat autoimmune and inflammatory disorders.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

Elevated fat and cholesterol levels found in a typical American-style diet play an important role in the growth and spread of breast cancer, say researchers at the Kimmel Cancer Center at Jefferson.

7 Jan 2011

CeNeRx commences TriRima Phase II trial for treatment resistant depression

CeNeRx BioPharma, today reported that it has initiated a Phase II trial of its new formulation of TriRima, the company's novel antidepressant in development as monotherapy for treatment resistant depression.

7 Jan 2011

Robo4 molecule may improve bone marrow transplants: Study

Researchers at the University of California, Santa Cruz, have identified a key molecule for establishing blood stem cells in their niche within the bone marrow. The findings, reported in the January issue of Cell Stem Cell, may lead to improvements in the safety and efficiency of bone marrow transplants.

7 Jan 2011

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Altheus Therapeutics, announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis.

6 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

A current New England Journal of Medicine study indicates that the use of the PARP inhibitor iniparib in combination with standard chemotherapy to treat metastatic triple-negative breast cancer offers a significant increase in clinical benefit, a measure of durable response or disease stabilization, as well as an increase in progression-free survival.

6 Jan 2011

Medical experts issue warning about common practice of tablet splitting

Medical experts have issued a warning about the common practice of tablet splitting, after a study found that nearly a third of the split fragments deviated from recommended dosages by 15 per cent or more.

6 Jan 2011

Opexa completes meetings with FDA regarding planned development program for Tovaxin

Opexa Therapeutics, Inc., a leading cell therapy company developing Tovaxin for multiple sclerosis, today announced the successful completion of two separate meetings with the U.S. Food and Drug Administration regarding the Company's planned development program for Tovaxin.

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

OpEds: Sebelius, Fla. Attorney General, USA Today, Wash Post opine about repeal strategies

Over the past nine months, I've traveled around the country and seen the benefits of this law firsthand. Unless we want to take coverage away from cancer patients, reduce oversight for insurance companies, raise prescription drug costs for seniors, weaken Medicare, add $1 trillion to the deficit and undo dozens of other reforms that are improving health around the country, we can't afford repeal (Kathleen Sebelius, 1/5).

6 Jan 2011

Drugs News and Research

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

Opinions: Global health top foreign policy issue; Global food security; Opiate-substitution programs in Eastern Europe; Feed the future; Foreign aid lessons

HRG protein inhibits tumor growth and metastasis: Study

Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan

X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Virdante Pharmaceuticals receives US key patent for Sialic Switch technology

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

CeNeRx commences TriRima Phase II trial for treatment resistant depression

Robo4 molecule may improve bone marrow transplants: Study

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

Medical experts issue warning about common practice of tablet splitting

Opexa completes meetings with FDA regarding planned development program for Tovaxin

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

OpEds: Sebelius, Fla. Attorney General, USA Today, Wash Post opine about repeal strategies

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News